The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy – 5-year follow-up

Table 4 Predictors of death in single-factor logistic regression

Categorical variable	Death (%)	Survival (%)	p
No statin treatment	78	21	0.006
Leg edema	72	27	0.027
Hepatomegaly	66	33	0.009
No beta-blocker therapy	87.5	12.5	0.001
Renal failure	80	20	0.025
Re-hospitalizations	81	18	0.001
Quantitative variable	With death (median; Q25–Q75)	Without death (median; Q25–Q75)	p
BMI 1	24; 24–26	30; 25–32	0.002
BMI 2	24; 23–26	30; 25–32	0.003
NT-proBNP 1*	2771; 1500–5013	980; 500–2130	0.001
NT-proBNP 2	2900; 1296–4421	766; 470–1680	0.001
LVEF 1	27; 21–29	32; 26–38	0.01
LVEF 2	30; 22–31	32; 28–40	0.03
LVsD 2	6.2; 5.3–6.7	5.3; 4.5–5.9	0.01
LVdD 2	7.6; 6.7–8.4	6.6; 6.0–7.2	0.003
MR 1	2; 1–3	1; 0–1	0.001
MR 2	2; 1–3	1; 0–1	0.001

*1 – for variables assessed after inclusion; 2 – for variables assessed after 2 months.
Q25–Q75: quartiles 25% and 75%.
ABBREVIATIONS: BMI body mass index; NT-proBNP N-terminal pro-brain natriuretic peptide; LVEF left ventricular ejection fraction; LVsD left ventricular systolic diameter; LVdD left ventricular diastolic diameter; MR mitral regurgitation.

ISSN: 1476-511X